La Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. In December 2017, GIAPREZA™ (angiotensin II) was approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. In August 2019, GIAPREZA was approved by the European Commission (EC) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. LJPC-0118 (artesunate) is La Jolla's investigational product for the treatment of severe malaria.
Company profile
Ticker
LJPC
Exchange
Website
CEO
Larry Edwards
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
La Jolla Pharma, LLC • Tetraphase Pharmaceuticals, Inc. • La Jolla Pharmaceutical Holdings, LLC • Tetraphase Pharma Securities, Inc. • La Jolla Pharmaceutical Australia Pty Ltd • La Jolla Pharmaceutical I B.V. • La Jolla Pharmaceutical II B.V. • La Jolla Pharmaceutical III B.V. • Tetraphase Ireland Limited ...
IRS number
330361285
LJPC stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
1 Sep 22
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Aug 22
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Aug 22
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Aug 22
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Aug 22
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Aug 22
25-NSE
Exchange delisting
22 Aug 22
8-K
Termination of a Material Definitive Agreement
22 Aug 22
SC 14D9/A
Tender offer solicitation (amended)
22 Aug 22
SC TO-T/A
Third party tender offer statement (amended)
22 Aug 22
Latest ownership filings
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 23
SC 13D/A
GARDNER LEWIS ASSET MANAGEMENT L P
29 Aug 22
SC 13D
GARDNER LEWIS ASSET MANAGEMENT L P
29 Aug 22
4
Robert Rosen
24 Aug 22
4
DAVID A RAMSAY
24 Aug 22
4
KEVIN C TANG
24 Aug 22
4
Larry G. Edwards
24 Aug 22
4
Michael S Hearne
24 Aug 22
4
Laura L. Johnson
24 Aug 22
4
Craig A Johnson
24 Aug 22
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q4 2022
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
RTW Investments | 0.00 | $0.00 |